Lead sponsor
Region Skane
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
1
Trials led
1
Ongoing
200
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Trials by status
Active, not recruiting
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Semaglutide and Dapagliflozin in Diabetic Patients With Different PathophysiologyHbA1c ≥6.5%Ph 2Active, not recruiting200